PT - JOURNAL ARTICLE AU - Lima, Alex Ranieri Jerônimo AU - Ribeiro, Gabriela AU - Viala, Vincent Louis AU - de Lima, Loyze Paola Oliveira AU - Martins, Antonio Jorge AU - Santos Barros, Claudia Renata dos AU - Marqueze, Elaine Cristina AU - de Souza Todao Bernardino, Jardelina AU - Moretti, Debora Botequio AU - Rodrigues, Evandra Strazza AU - Santos, Elaine Vieira AU - Brassaloti, Ricardo Augusto AU - de Lello Rocha Campos Cassano, Raquel AU - Mariani, Pilar Drummond Sampaio Corrêa AU - Clemente, Luan Gaspar AU - Assato, Patricia Akemi AU - Silva da Costa, Felipe Allan da AU - Poleti, Mirele Daiana AU - Lesbon, Jessika Cristina Chagas AU - Mattos, Elisangela Chicaroni AU - Banho, Cecilia Artico AU - Sacchetto, Lívia AU - Moraes, Marília Mazzi AU - Palmieri, Melissa AU - da Silva, Fabiana Erica Vilanova AU - Grotto, Rejane Maria Tommasini AU - Souza-Neto, Jayme A. AU - Giovanetti, Marta AU - de Alcantara, Luiz Carlos Junior AU - Nogueira, Maurício Lacerda AU - Fukumasu, Heidge AU - Coutinho, Luiz Lehmann AU - Kashima, Simone AU - Neto, Raul Machado AU - Covas, Dimas Tadeu AU - Slavov, Svetoslav Nanev AU - Elias, Maria Carolina AU - Sampaio, Sandra Coccuzzo TI - SARS-CoV-2 genomic monitoring in the São Paulo State unveils new sublineages of the AY.43 strain AID - 10.1101/2021.11.29.21266819 DP - 2021 Jan 01 TA - medRxiv PG - 2021.11.29.21266819 4099 - http://medrxiv.org/content/early/2021/11/30/2021.11.29.21266819.short 4100 - http://medrxiv.org/content/early/2021/11/30/2021.11.29.21266819.full AB - Delta VOC is highly diverse and more than 120 sublineages have been identified in Pango lineages with the continuous description of emerging ones. Brazil is now one of the most vaccinated countries against SARS-CoV-2 in the world which can enhance the emergence of viral mutations related to improved viral fitness. In this study, we identified two novel sublineages of the AY.43 lineage which were classified as AY.43.1 and AY.43.2 as observed on the specific clustering on the obtained phylogenetic tree. The novel sublineages were defined by the following characteristic nonsynonymous mutations ORF1ab:A4133V and ORF3a:T14I for AY.43.1 and ORF1ab:G1155C for AY.43.2. The majority of the analyzed sequences of both lineages were Brazilian, which shows that probably these two emerging sublineages have Brazilian origin. It is still unknown how these two sublineages are disseminated in São Paulo State and Brazil and their potential impact on the ongoing vaccination process. However, the performed study reinforces the importance of the SARS-CoV-2 genome monitoring for timely identification of emerging SARS-CoV-2 variants which can impact the ongoing SARS-CoV-2 vaccination and public health policies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Butantan Foundation, Fundação de Amparo à Pesquisa do Estado de São Paulo (Grant Numbers: 2020/10127; 2020/06441-2), Fundação Hemocentro Ribeirão PretoAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Ethics Committee of the Faculty of Medicine of Ribeirao Preto, University of Sao Paulo (CAAE: 50367721.7.1001.5440).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGenomes used in this study can be obtained from GISAID, using accession ID present in Supplementary Files 1 and 2. https://repositorio.butantan.gov.br/handle/butantan/3990?locale=en